Education
About Us
Working with TipRanks
Follow Us
Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
RESEARCH TOOLSreports
OTLC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.07
Previous CloseN/A
Volume643.67K
Average Volume (3M)42.98K
Market Cap
$20.90M
Enterprise Value$11.61M
Total Cash (Recent Filing)$79.17K
Total Debt (Recent Filing)$16.75M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
May 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding408,292,450
10 Day Avg. Volume93,605
30 Day Avg. Volume42,984
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.60
Price to Sales (P/S)0.00
P/FCF Ratio-4.47
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue165.89
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oncotelic Therapeutics News
PremiumCompany Announcements
Oncotelic Therapeutics Delays Yearly Report Filing
PremiumCompany Announcements
Oncotelic Therapeutics Secures Funds Through Equity SalesOptions Prices
Currently, No data available
---
Ownership Overview
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.02 and its highest was $0.07 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $20.90M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is May 26, 2025 which is 26 days ago.
How were Oncotelic Therapeutics’s earnings last quarter?
Oncotelic Therapeutics released its earnings results on Apr 16, 2025. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 408,292,450 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Oncotelic Therapeutics reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (OTLC) is a biotechnology company focused on developing novel therapies for the treatment of cancer. The company operates within the healthcare sector, concentrating on oncology therapeutics. Its core products include investigational drugs and treatments targeting tumor progression and metastasis, with a particular emphasis on RNA therapeutics and immuno-oncology approaches.
Technical Analysis
Tempest Therapeutics
―
Pulmatrix
―
Annovis Bio
―
Elevation Oncology
―
Cognition Therapeutics
―